6533b7defe1ef96bd1275dc7
RESEARCH PRODUCT
T-bet as a possible therapeutic target in autoimmune disease
Markus F. NeurathBenno Weigmannsubject
Mice Inbred MRL lprTranscription GeneticTransgeneT cellCellular differentiationClinical BiochemistryMice TransgenicLymphocyte ActivationAutoimmune DiseasesInterferon-gammaMiceTh2 CellsCrohn DiseaseDrug DiscoverymedicineAnimalsLupus Erythematosus SystemicIL-2 receptorIntestinal MucosaMice KnockoutPharmacologyAutoimmune diseaseLupus erythematosusbusiness.industryZAP70Cell DifferentiationTh1 CellsColitisInflammatory Bowel Diseasesmedicine.diseaseCeliac DiseaseDisease Models Animalmedicine.anatomical_structureCTLA-4ImmunologyCytokinesMolecular MedicineT-Box Domain ProteinsbusinessTranscription Factorsdescription
The prominent role of pro-inflammatory cytokines produced by T helper-1 (T(H1)) cells in regulating autoimmune responses in vitro and in vivo has been demonstrated. Recent observations of T cell polarisation by regulatory transcription factors--especially T-bet (T-box expressed in T cells)--raise the question of their influence in controlling autoimmune diseases. Here, the authors summarise recent observations of the role of T-bet in controlling chronic inflammatory and autoimmune diseases and discuss the implications of these findings for future therapeutic approaches.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2002-12-01 | Expert Opinion on Therapeutic Targets |